Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Simon J Day a Leo
Pharmaceuticals, Princes Risborough, Buckinghamshire HP27 9RR, b ICRF Medical Statistics Group, Institute of Health Sciences,
Oxford OX3 7LF
Correspondence to: S J Day
| The first 150 words of the full text of this article appear below. |
Human behaviour is influenced by what we know or believe. In research there is a particular risk of expectation influencing findings, most obviously when there is some subjectivity in assessment, leading to biased results. Blinding (sometimes called masking) is used to try to eliminate such bias.
It is a tenet of randomised controlled trials that the treatment allocation for each patient is not revealed until the patient has irrevocably been entered into the trial, to avoid selection bias. This sort of blinding, better referred to as allocation concealment, will be discussed in a future statistics note. In controlled trials the term blinding, and in particular "double blind," usually refers to keeping study participants, those involved with their management, and those collecting and analysing clinical data unaware of the assigned treatment, so that they should not be influenced by that knowledge.
The relevance of blinding will vary according to circumstances.
Blinding
Read all Rapid Responses